Cargando…

Treatment with a Substance P Receptor Antagonist Is Neuroprotective in the Intrastriatal 6-Hydroxydopamine Model of Early Parkinson's Disease

Neuroinflammation and blood brain barrier (BBB) dysfunction have been implicated in the pathogenesis of Parkinson's disease (PD). The neuropeptide substance P (SP) is an important mediator of both neuroinflammation and BBB dysfunction through its NK1 receptor in a process known as neurogenic in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thornton, Emma, Vink, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3317489/ https://www.ncbi.nlm.nih.gov/pubmed/22485158 http://dx.doi.org/10.1371/journal.pone.0034138

Ejemplares similares

Paeonol Protection Against Intrastriatal 6-Hydroxydopamine Rat Model of Parkinson’s Disease
por: Ghalami, Jamileh, et al.
Publicado: (2021)

Substance P and its tachykinin NK1 receptor: a novel neuroprotective target for Parkinson's disease
por: Thornton, Emma, et al.
Publicado: (2015)

Antioxidant Effect of Alpha-Lipoic Acid in 6-Hydroxydopamine Unilateral Intrastriatal Injected Rats
por: Andreeva-Gateva, Pavlina, et al.
Publicado: (2020)

Longitudinal assessment of motor function following the unilateral intrastriatal 6-hydroxydopamine lesion model in mice
por: Sun, Xiuping, et al.
Publicado: (2022)

The Longitudinal Transcriptomic Response of the Substantia Nigra to Intrastriatal 6-Hydroxydopamine Reveals Significant Upregulation of Regeneration-Associated Genes
por: Kanaan, Nicholas M., et al.
Publicado: (2015)

Unilateral Intrastriatal 6-Hydroxydopamine Lesion in Mice: A Closer Look into Non-Motor Phenotype and Glial Response
por: Mendes-Pinheiro, Bárbara, et al.
Publicado: (2021)

Kinin Receptor Antagonists as Potential Neuroprotective Agents in Central Nervous System Injury
por: Thornton, Emma, et al.
Publicado: (2010)

Intrastriatal administration of coenzyme Q10 enhances neuroprotection in a Parkinson’s disease rat model
por: Park, Hyung Woo, et al.
Publicado: (2020)

Neuroprotective Effect of Intrastriatal Caffeic Acid Phenethyl Ester Treatment in 6-OH Dopamine Model of Parkinson's Disease in Rats
por: Soner, Burak Cem, et al.
Publicado: (2021)

Neuroprotective Effect of Pseudoginsenoside-F11 on a Rat Model of Parkinson's Disease Induced by 6-Hydroxydopamine
por: Wang, Jian Yu, et al.
Publicado: (2013)

Neuroprotective Effect of Quercetin Nanocrystal in a 6-Hydroxydopamine Model of Parkinson Disease: Biochemical and Behavioral Evidence
por: Ghaffari, Fatemeh, et al.
Publicado: (2018)

Neuroprotective Activity of Some Marine Fungal Metabolites in the 6-Hydroxydopamin- and Paraquat-Induced Parkinson’s Disease Models
por: Yurchenko, Ekaterina A., et al.
Publicado: (2018)

Early Experience with Autologous Intrastriatal Adrenal Medulla/Nerve Cografting in Parkinson's Disease
por: Watts, R. L., et al.
Publicado: (1992)

Tetramethylpyrazine Analogue T-006 Exerts Neuroprotective Effects against 6-Hydroxydopamine-Induced Parkinson's Disease In Vitro and In Vivo
por: Zhou, Hefeng, et al.
Publicado: (2019)

Neuroprotective Effects of Herbal Ethanol Extracts from Gynostemma pentaphyllum in the 6-Hydroxydopamine-Lesioned Rat Model of Parkinson's Disease
por: Choi, Hyun Sook, et al.
Publicado: (2010)

Neuroprotective effects of insulin-like growth factor-2 in 6-hydroxydopamine-induced cellular and mouse models of Parkinson’s disease
por: Zhang, Hai-Ying, et al.
Publicado: (2022)

Intrastriatal Grafting of Chromospheres: Survival and Functional Effects in the 6-OHDA Rat Model of Parkinson's Disease
por: Boronat-García, Alejandra, et al.
Publicado: (2016)

Further Characterization of Intrastriatal Lipopolysaccharide Model of Parkinson’s Disease in C57BL/6 Mice
por: Deng, Isaac, et al.
Publicado: (2021)

The Role of Substance P in Secondary Pathophysiology after Traumatic Brain Injury
por: Vink, Robert, et al.
Publicado: (2017)

Pre-α-pro-GDNF and Pre-β-pro-GDNF Isoforms Are Neuroprotective in the 6-hydroxydopamine Rat Model of Parkinson's Disease
por: Penttinen, Anna-Maija, et al.
Publicado: (2018)

Dual-Hit Model of Parkinson’s Disease: Impact of Dysbiosis on 6-Hydroxydopamine-Insulted Mice—Neuroprotective and Anti-Inflammatory Effects of Butyrate
por: Avagliano, Carmen, et al.
Publicado: (2022)

Africanized Bee Venom (Apis mellifera Linnaeus): Neuroprotective Effects in a Parkinson’s Disease Mouse Model Induced by 6-hydroxydopamine
por: Dantas, Camila G., et al.
Publicado: (2022)

Neuroprotective effects of intrastriatal injection of rapamycin in a mouse model of excitotoxicity induced by quinolinic acid
por: Saliba, Soraya Wilke, et al.
Publicado: (2017)

Region-Specific Neuroprotective Features of Astrocytes against Oxidative Stress Induced by 6-Hydroxydopamine
por: Asanuma, Masato, et al.
Publicado: (2019)

GDNF Receptor Agonist Alleviates Motor Imbalance in Unilateral 6-Hydroxydopamine Model of Parkinson’s Disease
por: Renko, Juho-Matti, et al.
Publicado: (2020)

Sea Anemone Kunitz-Type Peptides Demonstrate Neuroprotective Activity in the 6-Hydroxydopamine Induced Neurotoxicity Model
por: Sintsova, Oksana, et al.
Publicado: (2021)

Protective efficacy of P7C3-S243 in the 6-hydroxydopamine model of Parkinson's disease
por: De Jesús-Cortés, Héctor, et al.
Publicado: (2015)

Better Outcomes with Intranigral versus Intrastriatal Cell Transplantation: Relevance for Parkinson’s Disease
por: Droguerre, Marine, et al.
Publicado: (2022)

Mitochondrial Dynamics and Mitophagy in the 6-Hydroxydopamine Preclinical Model of Parkinson's Disease
por: Galindo, Maria F., et al.
Publicado: (2012)

Parkinson’s Disease and the Heart: Studying Cardiac Metabolism in the 6-Hydroxydopamine Model
por: Silva da Fonsêca, Victor, et al.
Publicado: (2023)

Neuroprotective Effects of Safflower Flavonoid Extract in 6-Hydroxydopamine-Induced Model of Parkinson’s Disease May Be Related to its Anti-Inflammatory Action
por: Lei, Hui, et al.
Publicado: (2020)

Neuroprotection with the Cannabidiol Quinone Derivative VCE-004.8 (EHP-101) against 6-Hydroxydopamine in Cell and Murine Models of Parkinson’s Disease
por: Burgaz, Sonia, et al.
Publicado: (2021)

Lesioning of the Striatum Reverses Motor Asymmetry in the 6-Hydroxydopamine Rodent Model of Parkinsonism
por: Friehs, G. M., et al.
Publicado: (1991)

Upregulation of Cysteine Protease Cathepsin X in the 6-Hydroxydopamine Model of Parkinson’s Disease
por: Pišlar, Anja, et al.
Publicado: (2018)

Pretreatment With Fragments of Substance-P or With Cholecystokinin Differentially Affects Recovery From Sub-Total Nigrostriatal 6-Hydroxydopamine Lesion
por: Nikolaus, S., et al.
Publicado: (1999)

Berberine chloride pretreatment exhibits neuroprotective effect against 6-hydroxydopamine-induced neuronal insult in rat
por: Negahdar, Feraidoon, et al.
Publicado: (2015)

Design, Synthesis, and Neuroprotective Effects of a Series of Pyrazolines against 6-Hydroxydopamine-Induced Oxidative Stress
por: Özdemir, Ahmet, et al.
Publicado: (2018)

Intrastriatal injection of Parkinson’s disease intestine and vagus lysates initiates α-synucleinopathy in rat brain
por: Yang, Zhaofei, et al.
Publicado: (2023)

Characterization of the resting-state brain network topology in the 6-hydroxydopamine rat model of Parkinson’s disease
por: Westphal, Robert, et al.
Publicado: (2017)

Antidepressant-Like Properties of Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinson’s Disease
por: Antipova, Veronica, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1nj55f26o31r02j904pblijei7